Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitorsFootnote^$

$ Presented at the 9th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, CMTPI-2017, 27–30 October 2017, Goa, India.

References

• C. Lopez-Otin and L.M. Matrisian, Emerging roles of proteases in tumour suppression, Nat. Rev. Cancer 7 (2007), pp. 800–808.
   PubMed Web of Science ®Google Scholar
• C.E. Brinckerhoff and L.M. Matrisian, Matrix metalloproteinases: A tail of a frog that became a prince, Nat. Rev. Mol. Cell Biol. 3 (2002), pp. 207–214.
   PubMed Web of Science ®Google Scholar
• R.H. Holm, P. Kennepohl, and E.I. Solomon, Structural and functional aspects of metal sites in biology, Chem. Rev. 96 (1996), pp. 2239–2314.
   PubMed Web of Science ®Google Scholar
• E.H. Olsen, B. Fadnes, I. Sylte, L.U. Hansen, and J.O. Winberg, Regulation of matrix metalloproteinase activity in health and disease, FEBS J. 278 (2011), pp. 28–45.
   PubMed Web of Science ®Google Scholar
• J.F. Fisher and S. Mobashery, Recent advances in MMP inhibitor design, Cancer Metast. Rev. 25 (2006), pp. 115–136.
   PubMed Web of Science ®Google Scholar
• P. Jain, C. Saravanan, and S.K. Singh, Sulphonamides: Deserving class as MMP inhibitors? Eur. J. Med. Chem. 60 (2013), pp. 89–100.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, A. Mukherjee, A. Saha, and T. Jha, Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview, Eur. J. Med. Chem. 129 (2017), pp. 72–109.
   PubMed Web of Science ®Google Scholar
• M.G. Belvisi and K.M. Bottomley, The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm. Res. 52 (2003), pp. 95–100.
   PubMed Web of Science ®Google Scholar
• G.H. Skrepnek and S.V. Skrepnek, Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma, Am. J. Manag. Care 10 (2004), pp. S129–S138.
   PubMed Web of Science ®Google Scholar
• J. Hu, P.E. Van den Steen, Q.X. Sang, and G. Opdenakker, Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases, Nat. Rev. Drug Discov. 6 (2007), pp. 480–498.
   PubMed Web of Science ®Google Scholar
• S. Chakrabarti and K.D. Patel, Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology, Exp. Lung Res. 31 (2005), pp. 599–621.
   PubMed Web of Science ®Google Scholar
• V. Dive, C.F. Cheng, A. Yiotakis, and E.D. Sturrock, Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? Curr. Pharm. Des. 15 (2009), pp. 3606–3621.
   PubMed Web of Science ®Google Scholar
• K. Holmbeck, P. Bianco, J. Caterina, S. Yamada, M. Kromer, S.A. Kuznetsov, M. Mankani, P.G. Robey, A.R. Poole, I. Pidoux, J.M. Ward, and H. Birkedal-Hansen, MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover, Cell 99 (1999), pp. 81–92.
   PubMed Web of Science ®Google Scholar
• L.M. Coussens, B. Fingleton, and L.M. Matrisian, Matrix metalloproteinase inhibitors and cancer-trials and tribulations, Science 295 (2002), pp. 2387–2392.
   PubMed Web of Science ®Google Scholar
• C. Gialeli, A.D. Theocharis, and N.K. Karamanos, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J. 278 (2011), pp. 16–27.
   PubMed Web of Science ®Google Scholar
• K. Kessenbrock, V. Plaks, and Z. Werb, Matrix metalloproteinases: Regulators of the tumor microenviroment, Cell 141 (2011), pp. 52–67.
   Web of Science ®Google Scholar
• C.M. Overall and O. Kleifeld, Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy, Nat. Rev. Cancer 6 (2006), pp. 227–239.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, and T. Jha, Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?, Pharmacol. Res. 122 (2017), pp. 8–19.
   PubMed Web of Science ®Google Scholar
• R. Renkiewicz, L. Qiu, C. Lesch, X. Sun, R. Devalaraja, T. Cody, E. Kaldjian, H. Welgus, and V. Baragi, Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats, Arthritis Rheum. 48 (2003), pp. 1742–1749.
   PubMed Web of Science ®Google Scholar
• I. Bertini, M. Fragai, and C. Luchinat, Intra- and interdomain flexibility in matrix metalloproteinases: Functional aspects and drug design, Curr. Pharm. Des. 15 (2009), pp. 3592–3605.
   PubMed Web of Science ®Google Scholar
• F.J. Moy, P.K. Chanda, J. Chen, S. Cosmi, W. Edris, J.I. Levin, T.S. Rush, J. Wilhelm, and R. Powers, Impact of mobility on structure-based drug design for the MMPs, J. Am. Chem. Soc. 124 (2002), pp. 12658–12659.
   PubMed Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors, J. Pharm. Pharmacol. 65 (2013), pp. 1541–1554.
   PubMed Web of Science ®Google Scholar
• A.K. Halder, S. Mallick, D. Shikha, A. Saha, K.D. Saha, and T. Jha, Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity, RSC Adv. 5 (2015), pp. 72373–72386.
   Web of Science ®Google Scholar
• N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem. 24 (2016), pp. 4291–4309.
   PubMed Web of Science ®Google Scholar
• T. Jha, S. Basu, A.K. Halder, N. Adhikari, and S. Samanta, Possible anticancer agents: Synthesis, pharmacological activity, and molecular modeling studies on some 5-N-substituted-2-N-(substituted benzenesulphonyl)-L(+) glutamines, Med. Chem. Res. 26 (2017), pp. 1437–1458.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Understanding chemico-biological interactions of glutamate MMP-2 inhibitors through rigorous alignment-dependent 3D-QSAR analyses, ChemistrySelect 2 (2017), pp. 7888–7898.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in-house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. (2017), in press. DOI: 10.1007/s11224-017-1028-6.
   Google Scholar
• A. Mukherjee, N. Adhikari, and T. Jha, A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line, Eur. J. Med. Chem. 141 (2017), pp. 37–50.
   PubMed Web of Science ®Google Scholar
• S. Begum and P.G.R. Achary, Simplified molecular input line entry system-based: QSAR modelling for MAP kinase-interacting protein kinase (MNK1), SAR QSAR Environ. Res. 26 (2015), pp. 343–361.
   PubMed Web of Science ®Google Scholar
• C.W. Yap, PaDEL–descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474.
   PubMed Web of Science ®Google Scholar
• SYBYL-X 2.0 Software, Tripos Inc., St. Louis. MO, 2012. Software available at https://www.certara.com.
   Google Scholar
• R.B. Darlington, Regression and Linear Models, McGraw-Hill, New York, 1990.
   Google Scholar
• The simple, user-friendly and reliable online standalone tools freely available at http://teqip.jdvu.ac.in/QSAR_Tools/ and http://dtclab.webs.com/software-tools.
   Google Scholar
• O. Raevsky, A. Sapegin, and N. Zefirov, The QSAR discriminant-regression model, Mol. Inform. 13 (1994), pp. 412–418.
   Google Scholar
• S.A. Amin, N. Adhikari, T. Jha, and S. Gayen, First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington’s disease: A proposal to chemists!, Bioorg. Med. Chem. Lett. 26 (2016), pp. 5712–5718.
   PubMed Web of Science ®Google Scholar
• A. Perez-Garrido, A.M. Helguera, F. Borges, M.N. Cordeiro, V. Rivero, and A.G. Escudero, Two new parameters based on distances in a receiver operating characteristic chart for the selection of classification models, J. Chem. Inf. Model. 51 (2011), pp. 2746–2759.
   PubMed Web of Science ®Google Scholar
• M. Gálvez-Llompart, M.C. Recio, and R. García-Domenech, Topological virtual screening: A way to find new compounds active in ulcerative colitis by inhibiting NF-κB, Mol. Divers. 15 (2011), pp. 917–926.
   PubMed Web of Science ®Google Scholar
• T. Fawcett, An introduction to ROC analysis, Patt. Recog. Lett. 27 (2006), pp. 861–874.
   Web of Science ®Google Scholar
• A.E. Klon, J.F. Lowrie, and D.J. Diller, Improved naive Bayesian modelling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction, J. Chem. Inf. Model. 46 (2006), pp. 1945–1956.
   PubMed Web of Science ®Google Scholar
• L.L. Liu, J. Lu, Y. Lu, M.Y. Zheng, X.M. Luo, W.L. Zhu, H.L. Jiang, and K.X. Chen, Novel Bayesian classification models for predicting compounds blocking hERG potassium channels, Acta Pharmacol. Sinica 35 (2014), pp. 1093–1102.
   PubMed Web of Science ®Google Scholar
• Discovery Studio 3.0, Accelrys Inc, San Diego, CA, 2011. Software available at https://www.accelrys.com
   Google Scholar
• C. Zhang, C. Du, Z. Feng, J. Zhu, and Y. Li, Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4, Chem. Biol. Drug Des. 85 (2015), pp. 119–136.
   PubMed Web of Science ®Google Scholar
• S. Yu, J. Yuan, J. Shi, X. Ruan, T. Zhang, Y. Wang, and Y. Du, HQSAR and topomer CoMFA for predicting melanocortin-4 receptor binding affinities of trans-4-(4-chlorophenyl) pyrrolidine-3-carboxamides, Chemometr. Intell. Lab. Sys. 146 (2015), pp. 34–41.
   Web of Science ®Google Scholar
• N. Adhikari, A.K. Halder, C. Mondal, and T. Jha, Exploring structural requirements of aurone derivatives as antimalarials by validated DFT-based QSAR, HQSAR, and COMFA–COMSIA approach, Med. Chem. Res. 22 (2013), pp. 6029–6045.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, T.S. Shokouhi, M.R. Ganjali, P. Norouzi, and J. Shadmanesh, 2D and 3D quantitative structure-activity relationship study of hepatitis C virus NS5B polymerase inhibitors by comparative molecular field analysis and comparative molecular similarity indices analysis methods, J. Chem. Inf. Model. 54 (2014), pp. 2902–2914.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• B. Bush and R. Nachbar Jr, Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA, J. Comput. Aided. Mol. Des. 7 (1993), pp. 587–619.
   PubMed Web of Science ®Google Scholar
• P. Tosco and T. Balle, Open3DQSAR: A new open–source software aimed at high-throughput chemometric analysis of molecular interaction fields, J. Mol. Model. 17 (2011), pp. 201–208.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modelling techniques, J. Biomol. Struct. Dyn. (2017), in press. https://doi.org/10.1080/07391102.2017.1288659.
   Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
   PubMed Web of Science ®Google Scholar
• A. Tropsha, P. Gramatica, and V.K. Gombar, The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models, QSAR Comb. Sci. 22 (2003), pp. 69–77.
   Google Scholar
• V. Consonni, D. Ballabio, and R. Todeschini, Comments on the definition of the Q2 parameter for QSAR validation, J. Chem. Inf. Model. 49 (2009), pp. 1669–1678.
   PubMed Web of Science ®Google Scholar
• V. Consonni, D. Ballabio, and R. Todeschini, Evaluation of model predictive ability by external validation techniques, J. Chemometr. 24 (2010), pp. 194–201.
   Web of Science ®Google Scholar
• I. Svab, D. Alexandru, G. Vitos, and M.L. Flonta, Binding affinities for sulfonamide inhibitors with matrix metalloproteinase-2 using a linear response method, J. Cell. Mol. Med. 8 (2004), pp. 551–562.
   PubMed Web of Science ®Google Scholar
• Y. Feng, J.J. Likos, L. Zhu, H. Woodward, G. Munie, J.J. McDonald, A.M. Stevens, C.P. Howard, G.A. De Crescenzo, D. Welsch, H.S. Shieh, and W.C. Stallings, Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor, Biochim. Biophys. Acta 1598 (2002), pp. 10–23.
   PubMed Web of Science ®Google Scholar
• R.B. Aher and K. Roy, First report on exploring classification and regression based QSAR modelling of Plasmodium falciparum glycogen synthase kinase (PfGSK-3) inhibitors, SAR QSAR Env. Res. 26 (2015), pp. 959–976.
   PubMed Web of Science ®Google Scholar
• R. Todeschini and V. Consonni, Molecular descriptors for chemoinformatics, 2 volumes, WILEY-VCH, Weinheim, Germany, 2009.
   Google Scholar
• A. Jamloki, C. Karthikeyan, N.S.H.N. Moorthy, and P. Trivedi, QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase, Bioorg. Med. Chem. Lett. 16 (2006), pp. 3847–3854.
   PubMed Web of Science ®Google Scholar
• J. Zheng, R. Wen, and D. Guillaume, Three-dimensional quantitative structure-activity relationship (CoMFA and CoMSIA) studies on galardin derivatives as gelatinase A (matrix metalloproteinase 2) inhibitors, J. Enz. Inhib. Med. Chem. 23 (2008), pp. 445–453.
   PubMed Web of Science ®Google Scholar
• H. Zhu, H. Fang, X. Cheng, Q. Wang, L. Zhang, J. Feng, and W. Xu, 3D-QSAR study of pyrrolidine derivatives as matrix metalloproteinase-2 inhibitors, Med. Chem. Res. 18 (2009), pp. 683–701.
   Web of Science ®Google Scholar
• O. Nicolotti, M. Catto, I. Giangreco, M. Barletta, F. Leonetti, A. Stefanachi, L. Pisani, S. Cellamare, P. Tortorella, F. Loiodice, and A. Carotti, Design, synthesis and biological evaluation of 5-hydroxy, 5-substitutedpyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9, Eur. J. Med. Chem. 58 (2012), pp. 368–376.
   PubMed Web of Science ®Google Scholar
• K.M. Turra, D.P. Rivelli, S.B. de Moraes Barros, and K.F.M. Pasqualoto, Predicting novel antitumor agents: 3D-pharmacophore mapping of b-N-biaryl ether sulfonamide-based hydroxamates as potentially MMP-2 inhibitors, Mol. Inform. 33 (2014), pp. 573–587.
   PubMed Web of Science ®Google Scholar
• H.Y. Qiu, Z.C. Wang, P.F. Wang, X.Q. Yan, X.M. Wang, Y.H. Yang, and H.L. Zhu, Design, synthesis, evaluation and 3D-QSAR analysis of benzosulfonamide benzenesulfonates as potent and selective inhibitors of MMP-2, RSC Adv. 4 (2014), pp. 39214–39225.
   Web of Science ®Google Scholar
• X.Q. Yan, Z.C. Wang, Z. Li, P.F. Wang, H.Y. Qiu, L.W. Chen, X.Y. Lu, P.C. Lv, and H.L. Zhu, Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis, Bioorg. Med. Chem. Lett. 25 (2015), pp. 4664–4671.
   PubMed Web of Science ®Google Scholar
• M. Abbasi, F. Ramezani, M. Elyasi, H. Sadeghi-Aliabadi, and M. Amanlou, A study on quantitative structure–activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold, DARU J. Pharmaceut. Sci. 23 (2015), p. 29.
   Google Scholar
• J. Zhang, X.J. Wang, Z.K. Dong, S.Q. Wang, W.R. Xu, J.W. Fu, X.C. Cheng, and R.L. Wang, CoMFA/CoMSIA and molecular docking studies of novel matrix metalloproteinase-2 inhibitors based on L-tyrosine scaffold, Lett. Drug Des. Discov. 13 (2016), pp. 376–386.
   Web of Science ®Google Scholar
• R. Kiyama, Y. Tamura, F. Watanabe, H. Tsuzuki, M. Ohtani, and M. Yodo, Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors, J. Med. Chem. 42 (1999), pp. 1723–1738.
   PubMed Web of Science ®Google Scholar